An observational study in Health Care Associated Infection, sponsored by Gehad Salah El-Den Mahmoud Mohammad. Completed at 1 site in Egypt. Open to participants aged 1 Day to 28 Days. Per ClinicalTrials.gov, last updated 2020-01-03.
Sponsored by Gehad Salah El-Den Mahmoud Mohammad · Observational
Healthcare - Associated Infection Surveillance In Neonatal Intensive Care Unit of Assiut University Children's Hospital.The objective of study is to determine the incidence, infection sites, causative organisms and risk factors related to healthcare-associated infections in NICU in Assiut University Children hospital.
Nosocomial infections (NIs) are a major public health problem worldwide . Nosocomial infections are those acquired in or associated with hospitals. They are also known as hospital-acquired or healthcare-associated infections. The usual definition of a hospital-acquired infection is one that was not present or incubating when the patient was admitted to a hospital or healthcare facility; where there is doubt, a cut-off period of 48 hours after admission is used.The terms hospital-acquired and healthcare-associated are often used interchangeably, but 'healthcare-associated' also has the wider meaning of any infection acquired as a result of healthcare in any setting.
Nosocomial infections are common, and may be serious or fatal. Some are unavoidable but doctors' duty of care to their patients extends to fundamental matters such as basic hygiene, which may prevent patients becoming infected, and avoidance of unnecessary antibiotics, to discourage development of resistance Health care-associated infections (HC-AIs) are a major cause of morbidity and mortality in neonatal intensive care units (NICUs) and lead to increases in hospital length of stay and treatment cost. Higher nosocomial infection incidence in NICUs was related to longer duration of hospital stay, and invasive interventions and medical treatments. HC-AIs, especially device-associated health care-associated infections (DA-HAIs), were also common in newborns because of their insufficient immune system and mechanical barriers, as well as lack of protective flora
285 studies on the registry are indexed under Cross Infection; 48 are open to participants now.
This study's enrollment of 100 is below the median of 351 across 115 observational studies indexed under Cross Infection.
Browse Cross Infection studies →This is the only study on the registry with Gehad Salah El-Den Mahmoud Mohammad as lead sponsor.
Counted across the registry records on this site, refreshed daily.
This is a prospective clinical study covered a period of 12 months in a tertiary neonatal intensive care unit in NICU of Assiut university children's hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Detect incidence of nosocomial infection in NICU
To detect impact of nosocomial infection on outcome of neonates admitted in NICU
Time frame: 1 year
Ran from Dec 2017 to primary completion in Oct 2019, 22 months.
Of 56 non-industry observational studies under Cross Infection, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 65. This study's 22 months is below that.
Counting every sponsor, half of 56 studies reached it within 28 months; a quarter within 17 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.